Does the media favor SNDX or PRLD?

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 3 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Prelude Therapeutics' score of 0.26 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ANAB or PRLD?

In the previous week, Prelude Therapeutics had 2 more articles in the media than AnaptysBio. MarketBeat recorded 3 mentions for Prelude Therapeutics and 1 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.12 beat Prelude Therapeutics' score of 0.26 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, AAPG or PRLD?

Prelude Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.34 -$177.71M N/A N/A Prelude Therapeutics $12.14M 43.58 -$99.50M -$0.73 N/A

Is AAPG or PRLD more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Prelude Therapeutics N/A -75.35% -44.39%

Is PRLD or BCAX more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Bicara Therapeutics N/A -41.49% -38.59%

Does the media prefer PRLD or BCAX?

In the previous week, Bicara Therapeutics had 5 more articles in the media than Prelude Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 3 mentions for Prelude Therapeutics. Bicara Therapeutics' average media sentiment score of 0.64 beat Prelude Therapeutics' score of 0.26 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or PRLD?

In the previous week, Intellia Therapeutics had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 3 mentions for Prelude Therapeutics. Intellia Therapeutics' average media sentiment score of 1.21 beat Prelude Therapeutics' score of 0.26 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prelude Therapeutics (PRLD) Competitors

$6.63 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

PRLD vs. SNDX, ANAB, AAPG, BCAX, and NTLA

Should you buy Prelude Therapeutics stock or one of its competitors? Prelude Therapeutics's main competitors and comparable companies include Syndax Pharmaceuticals (SNDX), AnaptysBio (ANAB), Ascentage Pharma Group International (AAPG), Bicara Therapeutics (BCAX), and Intellia Therapeutics (NTLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prelude Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Syndax Pharmaceuticals currently has a consensus price target of $41.55, indicating a potential upside of 111.43%. Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 15.64%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Syndax Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Prelude Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Prelude Therapeutics' return on equity of -75.35% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Prelude Therapeutics	N/A	-75.35%	-44.39%

79.7% of Prelude Therapeutics shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Prelude Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.10	-$285.42M	-$2.51	N/A
Prelude Therapeutics	$12.14M	43.58	-$99.50M	-$0.73	N/A

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 3 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 1.02 beat Prelude Therapeutics' score of 0.26 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prelude Therapeutics beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

AnaptysBio currently has a consensus target price of $82.00, indicating a potential upside of 42.02%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 15.64%. Given AnaptysBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe AnaptysBio is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Prelude Therapeutics had 2 more articles in the media than AnaptysBio. MarketBeat recorded 3 mentions for Prelude Therapeutics and 1 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.12 beat Prelude Therapeutics' score of 0.26 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio has higher revenue and earnings than Prelude Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.29	-$13.23M	-$1.08	N/A
Prelude Therapeutics	$12.14M	43.58	-$99.50M	-$0.73	N/A

79.7% of Prelude Therapeutics shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prelude Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Summary

AnaptysBio and Prelude Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 173.11%. Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 15.64%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Ascentage Pharma Group International had 8 more articles in the media than Prelude Therapeutics. MarketBeat recorded 11 mentions for Ascentage Pharma Group International and 3 mentions for Prelude Therapeutics. Ascentage Pharma Group International's average media sentiment score of 0.35 beat Prelude Therapeutics' score of 0.26 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascentage Pharma Group International has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Prelude Therapeutics	N/A	-75.35%	-44.39%

79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Prelude Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.34	-$177.71M	N/A	N/A
Prelude Therapeutics	$12.14M	43.58	-$99.50M	-$0.73	N/A

Summary

Ascentage Pharma Group International beats Prelude Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Bicara Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Bicara Therapeutics' return on equity of -41.49% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Prelude Therapeutics has higher revenue and earnings than Bicara Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	43.58	-$99.50M	-$0.73	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

79.7% of Prelude Therapeutics shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Prelude Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 15.64%. Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 36.55%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, Bicara Therapeutics had 5 more articles in the media than Prelude Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 3 mentions for Prelude Therapeutics. Bicara Therapeutics' average media sentiment score of 0.64 beat Prelude Therapeutics' score of 0.26 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market.

Summary

Bicara Therapeutics beats Prelude Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Intellia Therapeutics presently has a consensus target price of $21.15, suggesting a potential upside of 64.74%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 15.64%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Prelude Therapeutics	N/A	-75.35%	-44.39%

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Prelude Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$59.51M	30.24	-$412.69M	-$3.36	N/A
Prelude Therapeutics	$12.14M	43.58	-$99.50M	-$0.73	N/A

In the previous week, Intellia Therapeutics had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 3 mentions for Prelude Therapeutics. Intellia Therapeutics' average media sentiment score of 1.21 beat Prelude Therapeutics' score of 0.26 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intellia Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Summary

Intellia Therapeutics beats Prelude Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$529.07M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-9.08	11.68	272.91	24.33
Price / Sales	43.58	1,377.87	639.20	97.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	6.08	17.70	11.38	6.42
Net Income	-$99.50M	-$22.72M	$3.47B	$348.89M
7 Day Performance	17.76%	2.73%	2.16%	0.51%
1 Month Performance	73.11%	9.63%	7.59%	4.84%
1 Year Performance	434.68%	54.98%	25.16%	17.04%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	1.5016 of 5 stars	$6.63 flat	$7.67 +15.6%	+434.7%	$529.07M	$12.14M	N/A	120
SNDX Syndax Pharmaceuticals	2.7342 of 5 stars	$19.83 +0.4%	$41.91 +111.3%	+21.0%	$1.76B	$172.35M	N/A	110	Analyst Forecast
ANAB AnaptysBio	2.5593 of 5 stars	$58.98 -1.2%	$82.00 +39.0%	+185.6%	$1.74B	$234.60M	N/A	100	Positive News
AAPG Ascentage Pharma Group International	4.0132 of 5 stars	$17.91 -1.6%	$46.43 +159.3%	-64.5%	$1.67B	$574.12M	N/A	600	Earnings Report Analyst Forecast
BCAX Bicara Therapeutics	2.1803 of 5 stars	$24.66 -1.1%	$32.40 +31.4%	+101.9%	$1.64B	N/A	N/A	32	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. SNDX, ANAB, AAPG, BCAX, and NTLA

How does Prelude Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Prelude Therapeutics compare to AnaptysBio?

Summary

How does Prelude Therapeutics compare to Ascentage Pharma Group International?

Summary

How does Prelude Therapeutics compare to Bicara Therapeutics?

Summary

How does Prelude Therapeutics compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. SNDX, ANAB, AAPG, BCAX, and NTLA

How does Prelude Therapeutics compare to Syndax Pharmaceuticals?

Do analysts rate SNDX or PRLD?

Which has more volatility and risk, SNDX or PRLD?

Is SNDX or PRLD more profitable?

Do institutionals & insiders have more ownership in SNDX or PRLD?

Which has better valuation & earnings, SNDX or PRLD?

Does the media favor SNDX or PRLD?

Summary

How does Prelude Therapeutics compare to AnaptysBio?

Which has more risk & volatility, ANAB or PRLD?

Do analysts prefer ANAB or PRLD?

Does the media refer more to ANAB or PRLD?

Which has stronger earnings & valuation, ANAB or PRLD?

Do insiders and institutionals believe in ANAB or PRLD?

Is ANAB or PRLD more profitable?

Summary

How does Prelude Therapeutics compare to Ascentage Pharma Group International?

Do analysts prefer AAPG or PRLD?

Does the media favor AAPG or PRLD?

Which has more risk and volatility, AAPG or PRLD?

Is AAPG or PRLD more profitable?

Do insiders & institutionals have more ownership in AAPG or PRLD?

Which has higher valuation & earnings, AAPG or PRLD?

Summary

How does Prelude Therapeutics compare to Bicara Therapeutics?

Is PRLD or BCAX more profitable?

Which has preferable earnings and valuation, PRLD or BCAX?

Do institutionals and insiders believe in PRLD or BCAX?

Do analysts prefer PRLD or BCAX?

Does the media prefer PRLD or BCAX?

Which has more risk & volatility, PRLD or BCAX?

Summary

How does Prelude Therapeutics compare to Intellia Therapeutics?

Do analysts prefer NTLA or PRLD?

Is NTLA or PRLD more profitable?

Do institutionals & insiders hold more shares of NTLA or PRLD?

Which has preferable earnings and valuation, NTLA or PRLD?

Does the media refer more to NTLA or PRLD?

Which has more risk and volatility, NTLA or PRLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools